RNAi therapy from Medicines Co., Alnylam cuts cholesterol by 54%, could compete with PCSK9 mAbs

The Medicines Co. announced data from a Phase III trial of inclisiran showing reductions in LDL-C that appear to be competitive with approved mAbs against PCSK9, but with a dosing advantage. Safety data from the study, which tested the RNAi therapeutic in patients with hypercholesterolemia and atherosclerotic CV disease or equivalent risk, also buttressed partner Alnylam's case for the safety of its RNAi platform.

The Medicines Co. (NASDAQ:MDCO) gained $4.35 (10%) to $46.31 Tuesday, adding about $345 million in market cap. The company presented the data Monday at the European Society of Cardiology meeting in Paris, after reporting last week that inclisiran met the Phase III ORION-11 trial's primary and secondary endpoints (see "Inclisiran Clears First Phase III Hurdle"). ...